Percorrer por autor "Mendes, Filipa"
A mostrar 1 - 3 de 3
Resultados por página
Opções de ordenação
- Assessment of carrier-free metallacarboranes for targeted radiation therapies PBFT and BNCT : comparative cellular effects and dosimetry studies with [o-FESAN]− in breast cancer cellsPublication . Di Maria, Salvatore; Pinheiro, Teresa; Alves, Luís Cerqueira; Bitonto, Valeria; Protti, Nicoletta; Crich, Simonetta Geninatti; Nishimura, Kai; Nakamura, Hiroyuki; Matos, António P.; Pinto, Catarina I. G.; Mendes, Filipa; Teixidor, Francesc; Viñas, Clara; Marques, FernandaBackground: Ferrabis(dicarbollide) ([o-FESAN]−) in combination with proton–boron fusion therapy (PBFT) or boron neutron capture therapy (BNCT) are promising alternative radiation modalities for the treatment of breast cancer. The aim of this study was to explore the underlying effects of [o-FESAN]− radio enhancement on breast cancer cells in vitro and in vivo, and to perform comparative dosimetry calculations. Methods: The cellular effects on SKBR-3 and MDA-MB-231 breast cancer cells and MDA-MB-231 xenograft-bearing nude mice induced by carrier-free [o-FESAN]− after BNCT or PBFT were evaluated following recommended protocols. Monte Carlo (MC) dosimetry calculations were performed at the cellular scale for both radiation modalities. Results: Selective retention of [o-FESAN]− within the cytoplasm and nucleus of SKBR-3 and MDA-MB-231 breast cancer cells is demonstrated. Moreover, in vivo studies with MDA-MB-231 xenograft-bearing nude mice show appreciable accumulation of [o-FESAN]− in the tumor. Both radiation modalities induce loss of cellular viability and survival. Comparative dosimetry studies between proton and neutron irradiation agree with the viability data, showing a good correlation between absorbed dose vs. cellular effects. In the case of PBFT, cell structural changes are likely due to necrosis caused by the production of reactive oxygen species (ROS). To explain the radio enhancement effects in more detail, other mechanisms should be taken into consideration. Conclusions: Our results validate the effectiveness of both PBFT and BNCT therapeutic modalities, warranting further studies on carrier-free [o-FESAN]− as a candidate drug for potential clinical translation of radio enhancers in binary radiation therapies.
- Fe/57Fe-metallacarboranes with radiosensitizing potential in breast cancer cell models : comparative study between high- (60Co) and low-energy (57Co) gamma radiation sourcesPublication . Maria, Salvatore Di; Engrácia, Diogo M.; Pinto, Catarina I. G.; Waerenborgh, João C.; Vieira, Bruno J. C.; Santos, Pedro; Pinheiro, Teresa; Nuez-Martínez, Miquel; Matos, António P.; Mendes, Filipa; Teixidor, Francesc; Viñas, Clara; Marques, FernandaBackground: Radiosensitizers can be used to enhance tumor response and mitigate toxicity in healthy tissues during radiation therapy. This study investigates the radiosensitizing potential of the metallacarborane Fe/57Fe-ferrabisdicarbollide in SK-BR-3 and MDA-MB-231 breast cancer cells, using two distinct gamma-photon sources: high-dose 60Co (2.08 Gy) and low-dose 57Co (37.55 mGy, 57Fe Mössbauer effect). Methods: We evaluated cell viability and survival in 2D monolayer and 3D spheroid cultures, as well as the mechanism of cell death (ROS production, apoptosis or necrosis). Computational dosimetry was used to calculate the average absorbed dose. Results: In 2D models, both radiation sources induced reduced viability and increased ROS, with distinct cell death patterns dependent on the source (apoptosis or necrosis). Comparing 2D and 3D MDA-MB-231 models revealed that spheroid survival was significantly more impaired. The low-dose 57Co source caused a significant radiosensitization in MDA-MB-231 spheroids, dramatically impacting viability and survival. This effect is attributed to the Mössbauer effect, where the resonant absorption of 14.41 keV radiation by 57Fe leads to a massive, localized dose enhancement. The subsequent cascade of Auger and conversion electrons (local high LET) caused significantly greater cellular damage than sparse photon radiation. Conclusions: Fe/57Fe-ferrabisdicarbollide demonstrates a potent radiosensitizing effect depending on the cell model and the radiation source used. Crucially, the observed radiosensitization allows for the development of a new, more efficient cancer radiotherapy approach that can achieve therapeutic efficacy using a significantly lower radiation dose to the patient. This paves the way for safer and better-tolerated cancer treatments.
- The Mössbauer effect using 57Fe-ferrabisdicarbollide ([o-57FESAN]−) : a glance into the potential of a low-dose approach for glioblastoma radiotherapyPublication . Buades, Ana B.; Pereira, Laura C. J.; Vieira, Bruno J. C.; Cerdeira, Ana C.; Waerenborgh, João C.; Pinheiro, Teresa; Matos, António P. A.; Pinto, Catarina G.; Guerreiro, Joana F.; Mendes, Filipa; Valic, Srecko; Teixidor, Francesc; Viñas, Clara; Marques, FernandaAlthough a variety of cancers are initially susceptible to chemotherapy, they eventually develop multi-drug resistance. To overcome this situation, more effective and selective treatments are necessary using anti-tumour agents that act in two or more ways and offer greater therapeutic benefits over single-mechanism entities. In this study, we report on treating cancer with Na[3,3′-57Fe(1,2-C2B9H11)2], which offers the possibility of dual action (radiation–drug combinations) to improve the clinical benefits and reduce healthy tissue toxicity. An approach to evaluating the potential of [o-57FESAN]− to treat glioblastoma using the Mössbauer effect is presented. As the therapeutic outcomes rely on the amount and distribution of [o-57FESAN]− inside the cells, several studies, using magnetization, Mössbauer spectroscopy and nuclear microscopy techniques, were performed to ascertain the uptake of [o-57FESAN]− in U87 glioblastoma cells. [o-57FESAN]− was found to be within the cells; 29% of its uptake was in the nuclear fraction, which is a particularly desirable target, because the nucleus is the cell's control centre where DNA and the transcription machinery reside. Irradiation studies with 2D and 3D cellular models of U87 cells showed that the growth inhibition effect observed was more pronounced when [o-57FESAN]− was used in combination with the Mössbauer effect in low total dose regimens, suggesting that this procedure either alone or as adjuvant may be useful for glioblastoma treatment.